Viela Bio has received FDA approval for Uplizna, an intravenous treatment for neuromyelitis optica spectrum disorder in certain adults.
The treatment, inebilizumab-cdon injection, is the second approved therapy for neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (anti-AQP4) antibody positive. The first was Soliris (eculizumab, Alexion Pharmaceuticals), which was approved in June 2019.
“We continue to remain highly committed to the development of additional safe and effective drugs for this rare and devastating disease,” Billy Dunn, MD, director of
Uncategorized